GlassScriptPhysician profile
David Larry Horwitz
NPI 1356759955
$1,090.85
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2021: $650.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $650.00 | 2021 | |
| Amgen INC. | $117.17 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $116.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $110.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $96.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Horwitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.